Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.27 USD | -2.43% | -3.63% | -9.11% |
May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
May. 20 | BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda | MT |
Evolution of the average Target Price on Day One Biopharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Day One Biopharmaceuticals, Inc.
HC Wainwright | |
Needham & Co. | |
JPMorgan Chase | |
Piper Sandler | |
Wedbush | |
Goldman Sachs | |
BofA Securities | |
Capital One Securities | |
Oppenheimer |
EPS Revisions
- Stock Market
- Equities
- DAWN Stock
- Consensus Day One Biopharmaceuticals, Inc.